TSI is leading development of a next-generation therapy to change the treatment paradigm for ischemic stroke and heart attack.
Current treatment options for patients experiencing a stroke or heart attack are limited. TSI is dedicated to transforming standards of care.
TSI’s sequential regimen embodies a novel approach to thrombolytic (clot-busting) therapy, enabling early, safe and reliable post-event treatment that should provide greater confidence to emergency medicine healthcare professionals, cardiologists and neurologists in treating ischemic strokes and heart attacks. Learn more by going here.
TSI’s treatment regimen, developed by world leaders in thrombolysis, was successfully studied in a Phase I safety trial, and will be studied in two Phase II confirmatory clinical trials.
What we do
The Facts
Ischemic heart disease and stroke are the world's biggest killers
Around 90% of all strokes are caused by blood clots
Someone dies of a stroke every 10 seconds
Fewer than 5% of stroke patients in the U.S. and fewer than 10% in Europe are treated